利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.017 秒)

    Mesothelioma Gene Therapy
    2.
    发明申请
    Mesothelioma Gene Therapy 审中-公开

    公开(公告)号：US20200164091A1

    公开(公告)日：2020-05-28

    申请号：US16739245

    申请日：2020-01-10

    申请人： Canji, Inc.

    发明人： William F. BENEDICT

    IPC分类号： A61K48/00 ,  C12N15/86 ,  C07K14/56 ,  A61K38/21 ,  A61K9/127 ,  A61K9/00

    摘要： The present invention provides a method for the treatment of lung cancer through the use of a recombinant gene therapy vector having a transgene encoding interferon. In particular it is noted that interferon when expressed by a recombinant gene therapy vectors possesses properties not associated with exogenously-manufactured interferon proteins. The present disclosure thus provides a method useful in the treatment of lung tumors such as mesothelioma, using a recombinant gene therapy vector having a transgene encoding interferon.

    Recombinant adenoviral vector and methods of use
    4.
    发明申请
    Recombinant adenoviral vector and methods of use 审中-公开
    重组腺病毒载体及使用方法

    公开(公告)号：US20040087027A1

    公开(公告)日：2004-05-06

    申请号：US10602258

    申请日：2003-06-23

    申请人： Canji, Inc.

    发明人： Richard J. Gregory ,  Ken N. Wills ,  Daniel C. Maneval

    IPC分类号： C12N007/00 ,  C12N015/86

    CPC分类号： C12N15/86 ,  A61K35/761 ,  A61K38/00 ,  A61K38/45 ,  A61K48/00 ,  C07K14/005 ,  C07K14/4746 ,  C12N7/00 ,  C12N2710/10321 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2830/85 ,  A61K2300/00

    摘要： This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).

    摘要翻译： 本发明提供一种重组腺病毒表达载体，其特征在于部分或完全缺失腺病毒蛋白IX DNA并具有编码外来蛋白或其功能片段或突变体的基因。 转化的宿主细胞和生产重组蛋白和基因治疗的方法也包括在本发明的范围内。 因此，例如，本发明的腺病毒载体可以含有外源基因，用于表达有效调节细胞周期的蛋白质，如p53，Rb或mitosin，或诱导细胞死亡，如条件性自杀基因 胸苷激酶。 （后者必须与胸苷激酶代谢物结合使用才能有效）。

    Recombinant adenoviral vector and methods of use
    5.
    发明申请
    Recombinant adenoviral vector and methods of use 失效

    公开(公告)号：US20040038404A1

    公开(公告)日：2004-02-26

    申请号：US10441510

    申请日：2003-05-19

    申请人： Canji, Inc.

    发明人： Richard J. Gregory ,  Ken N. Wills ,  Daniel C. Maneval

    IPC分类号： C12N015/861 ,  C12N007/00

    CPC分类号： C12N15/86 ,  A61K38/00 ,  C07K14/4746 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2830/85 ,  Y02A50/473

    摘要： This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).

    Adenoviral vectors having a protein IX deletion
    6.
    发明申请
    Adenoviral vectors having a protein IX deletion 审中-公开
    具有蛋白质IX缺失的腺病毒载体

    公开(公告)号：US20020137212A1

    公开(公告)日：2002-09-26

    申请号：US09860211

    申请日：2001-05-18

    申请人： Canji,Inc.

    发明人： Richard J. Gregory ,  Ken N. Wills ,  Daniel C. Maneval

    IPC分类号： C12N015/861 ,  C12N007/01

    CPC分类号： C07K14/4746 ,  A61K38/00 ,  C12N15/86 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2830/85

    摘要： This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).

    摘要翻译： 本发明提供一种重组腺病毒表达载体，其特征在于部分或完全缺失腺病毒蛋白IX DNA并具有编码外来蛋白或其功能片段或突变体的基因。 转化的宿主细胞和生产重组蛋白和基因治疗的方法也包括在本发明的范围内。 因此，例如，本发明的腺病毒载体可以含有外源基因，用于表达有效调节细胞周期的蛋白质，如p53，Rb或mitosin，或诱导细胞死亡，如条件性自杀基因 胸苷激酶。 （后者必须与胸苷激酶代谢物结合使用才能有效）。

    Aptamer-mediated regulation of gene expression
    7.
    发明申请
    Aptamer-mediated regulation of gene expression 失效
    适体介导的基因表达调控

    公开(公告)号：US20020115629A1

    公开(公告)日：2002-08-22

    申请号：US10036091

    申请日：2001-10-19

    申请人： Canji, Inc.

    发明人： Murali Ramachandra

    IPC分类号： A61K048/00 ,  C07H021/04

    CPC分类号： C12N15/115 ,  C12N15/63 ,  C12N15/635

    摘要： This invention provides methods of regulating gene expression. An aptamer is positioned in a nucleic acid molecule along with a sequence encoding a transcriptional regulatory polypeptide. The aptamer disrupts translation of the transcriptional regulatory polypeptide when contacted with an aptamer-binding ligand. Gene expression levels can be either increased or decreased by the disclosed methods, depending on whether the transcriptional regulatory polypeptide is a repressor or activator, and the degree of the effect is dependent upon the dose of the ligand. Nucleic acid molecules, expression cassettes, expression vectors and cells useful in the gene regulation methods are also provided.

    摘要翻译： 本发明提供调节基因表达的方法。 适配体与编码转录调节多肽的序列一起置于核酸分子中。 当与适体结合配体接触时，适体破坏转录调节多肽的翻译。 取决于转录调控多肽是否是抑制因子或激活剂，并且其作用程度取决于配体的剂量，所述方法可以增加或减少基因表达水平。 还提供了可用于基因调控方法的核酸分子，表达盒，表达载体和细胞。

    METHODS AND COMPOSITIONS FOR TREATMENT OF INTERFERON-RESISTANT TUMORS
    8.
    发明申请
    METHODS AND COMPOSITIONS FOR TREATMENT OF INTERFERON-RESISTANT TUMORS 有权

    公开(公告)号：US20210322572A1

    公开(公告)日：2021-10-21

    申请号：US17244835

    申请日：2021-04-29

    申请人： Canji Inc.

    发明人： William F. Benedict

    IPC分类号： A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K38/21 ,  C07K14/56 ,  C12N15/86

    摘要： The present invention provides a method for the treatment of “interferon resistant” tumors (i.e., tumors resistant to treatment with exogenously-administered interferon polypeptide) through the use of a non-replicating agent which induces human cells to express interferon species. In particular it is noted that inducing interferon expression in the patient's body possesses properties not associated with exogenously-produced intravenously-administered interferon proteins. The present invention further provides compositions useful in the treatment of cancer resistant to treatment with exogenous interferon polypeptide, by using a non-replicating agent which induces human cells to express interferon species, e.g., an antigenic, replication-deficient virus optionally carrying an interferon transgene.

    Adenoviral vectors having a protein IX deletion
    9.
    发明申请
    Adenoviral vectors having a protein IX deletion 审中-公开
    具有蛋白质IX缺失的腺病毒载体

    公开(公告)号：US20040266006A1

    公开(公告)日：2004-12-30

    申请号：US10766363

    申请日：2004-01-27

    申请人： Canji, Inc.

    发明人： Richard J. Gregory ,  Ken N. Wills ,  Daniel C. Maneval

    IPC分类号： C12N015/861 ,  C12N007/00

    CPC分类号： C12N15/86 ,  A61K35/761 ,  A61K38/00 ,  A61K38/45 ,  A61K48/00 ,  C07K14/005 ,  C07K14/4746 ,  C12N7/00 ,  C12N2710/10321 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2830/85 ,  A61K2300/00

    摘要： This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also are included within the scope of this invention. Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used in conjunction with a thymidine kinase metabolite in order to be effective).

    摘要翻译： 本发明提供一种重组腺病毒表达载体，其特征在于部分或完全缺失腺病毒蛋白IX DNA并具有编码外来蛋白或其功能片段或突变体的基因。 转化的宿主细胞和生产重组蛋白和基因治疗的方法也包括在本发明的范围内。 因此，例如，本发明的腺病毒载体可以含有外源基因，用于表达有效调节细胞周期的蛋白质，如p53，Rb或mitosin，或诱导细胞死亡，如条件性自杀基因 胸苷激酶。 （后者必须与胸苷激酶代谢物结合使用才能有效）。

    Method for selectively transducing pathologic mammalian cells using a tumor suppressor gene
    10.
    发明申请
    Method for selectively transducing pathologic mammalian cells using a tumor suppressor gene 审中-公开
    使用肿瘤抑制基因选择性转导病理性哺乳动物细胞的方法

    公开(公告)号：US20030077250A1

    公开(公告)日：2003-04-24

    申请号：US10076691

    申请日：2002-02-14

    申请人： Canji, Inc.

    发明人： H. Michael Shepard ,  Nancy Kan

    IPC分类号： A61K048/00 ,  C12N015/867

    CPC分类号： C07K14/4746 ,  A61K38/1709 ,  A61K48/00 ,  C07K14/47 ,  C12N2740/13043

    摘要： A method for transducing a pathologic hyperproliferative mammalian cell is provided by this invention. This method requires contacting the cell with a suitable retroviral vector containing a nucleic acid encoding a gene product having a tumor suppressive function. Also provided by this invention is a method for treating a pathology in a subject caused by the absence of, or the presence of a pathologically mutated tumor suppressor gene.

    摘要翻译： 用于转导病理过度增殖的哺乳动物细胞的方法由本发明提供。 该方法需要使细胞与含有编码具有肿瘤抑制功能的基因产物的核酸的合适的逆转录病毒载体接触。 本发明还提供了一种用于治疗由于不存在或存在病理突变的肿瘤抑制基因导致的受试者病理学的方法。